Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Gyeonggi-do
Clinical trial register · South Korea

Clinical Trials in Gyeonggi-do, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 87 Busan 16 Daegu 13 Incheon 13 Suwon 13
Narrow the registerReset
Recruitment status
Phase
Site location
Seoul87 Busan16 Daegu13 Incheon13 Suwon13
All 41 locations
Target enrolment
to

Trials with a site in Gyeonggi-do

8 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
Post Marketing Study on Pluvicto in Korea
NCT06514521Metastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals
Observational
278
Seongnam-si, Suwon, Busan, Gyeonggi-do, Seoul, Jeollanam
2025-04-18
Recruiting
Long-term Follow up Local Registry Study of Kymriah in South Korea
NCT06785818B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Novartis Pharmaceuticals
Observational
500
Bundang Gu, Seongnam-si, Gyeonggi-do, Incheon, Seoul, Busan, Jeollanam, Ulsan
2025-03-12
Recruiting
Novartis Pharmaceuticals
Phase 3
1,400
Bundang Gu, Gyeonggi-do, Seoul, Incheon, Seongnam Gyeonggi
2024-02-28
Recruiting
Asciminib RMP Study
NCT05943522Chronic Myeloid Leukemia
Novartis Pharmaceuticals
Observational
600
Wŏnju, Anyang-si, Bucheon-si, Uijeongbu-si, Gyeonggi-do, Incheon, Seoul, Suwon
2023-07-19
Recruiting
Novartis Pharmaceuticals
Observational
900
Cheonan Si, Daegu, Goyang-si, Suwon, Gyeonggi-do, Seoul, Busan, Daejeon
2022-06-29
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals
Phase 3
430
Jinju, Busan, Daegu, Gyeonggi-do, Incheon, Jeonju, Seoul, Ulsan
2021-04-09
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
404
Anyang, Daejeon, Gyeonggi-do, Jeju City, Seongnam-si, Seoul
2020-12-11
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Seoul, Wŏnju, Bundang Gu, Suwon, Gyeonggi-do, Cheongju-si, Incheon, Seongnam Gyeonggi
2018-12-07
Rows per page Showing 1–8 of 8
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/gyeonggi-do

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 8 of those studies with a site in Gyeonggi-do that also match the filters currently applied.

How many clinical trials are recruiting in Gyeonggi-do?

5 of the 8 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gyeonggi-do), 8 studies
PhaseStudiesRecruitingShare
Observational4450%
Phase 34150%

Most active sponsors

Lead sponsors with the most studies (Gyeonggi-do)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals85
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.